Adrian C. Bloor

Wimslow Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: June 16, 2026

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Journal: British journal of haematology

Published: December 08, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: June 16, 2025

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: May 05, 2025

Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT.

Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT.

Journal: Bone marrow transplantation

Published: April 18, 2025

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Journal: Blood cancer journal

Published: February 26, 2025

Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).

Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).

Journal: BMJ open

Published: January 29, 2025

Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party.

Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party.

Journal: HemaSphere

Published: December 28, 2024

UK consensus statement on the use of plerixafor in healthy stem cell donors.

UK consensus statement on the use of plerixafor in healthy stem cell donors.

Journal: British journal of haematology

Published: November 18, 2024

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.

Journal: Leukemia

Published: April 03, 2024

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.

Journal: Blood advances

Published: March 12, 2024

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Journal: The New England journal of medicine

Published: December 11, 2023

Showing 1-12 of 74

Last Updated: 09/26/2026